Tuesday, 29 October 2013

Acasti Strengthened With USPTO Patent Allowance

Acasti Pharma
TSX V: APO NASDAQ: ACST
Shares Outstanding: 79.4 million
Fully Diluted: 91.4 million
*****************************

Acasti Pharma announced this morning that the U.S. Patent & Trademark Office (USPTO) has allowed Acasti’s composition and use patent application entitled “Concentrated Therapeutic Phospholipid Compositions” (Publication # US20110160161).  

In the news release, Acasti declared that it “expects this allowance to be the last step before the USPTO officially grants the Patent, which Acasti anticipates will occur by the end of 2013.”

To be clear, this patent addresses a more concentrated or purified krill oil (compared to Neptune’s nutraceuticals), which is what Acasti is focused on with its Capre drug. It is separate from the announced Neptune patents on Phospholipid Compositions. Interestingly, Acasti’s patent does include neurodevelopmental diseases and neurodegenerative diseases, on which NeuroBioPharm (Neptune’s currently private subsidiary) will be focusing.

Here is more information on Neptune’s announced patents.
To read more information on Acasti’s patent application, click here- http://www.google.com/patents/US20110160161

The news release also announces that Acasti has been granted a “patent in South Africa, which is enforceable and valid until October 29, 2029.”

To view the full news release, please click here....